公开(公告)号：US20180237501A1

公开(公告)日：2018-08-23

申请号：US15902775

申请日：2018-02-22

Applicant: AMGEN INC.

Inventor： Christopher James SLOEY ,  Sekhar KANAPURAM ,  Huanchun CUI ,  Chio Mui CHAN ,  Elaheh BINABAJI

IPC: C07K16/06 ,  C07K16/22 ,  C07K1/36 ,  A61K39/395 ,  A61K47/18 ,  A61K9/00 ,  C07K1/16

CPC classification number: C07K16/065 ,  A61K9/0019 ,  A61K39/3955 ,  A61K39/39591 ,  A61K47/183 ,  C07K1/16 ,  C07K1/36 ,  C07K16/22 ,  C07K16/40 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/90

Abstract: Provided herein are formulations of PCSK9-binding polypeptides, such as those comprising evolocumab, that comprise N-acetyl arginine and have reduced viscosities when compared to formulations lacking N-acetyl arginine. Provided herein are also methods of formulating such compositions that are advantageous in that they conserve certain components. Such formulations comprising PCSK9-binding polypeptides can be administered to patients to treat and/or prevent PCSK9-related diseases, conditions, and disorders.

公开(公告)号：US20230226177A1

公开(公告)日：2023-07-20

申请号：US17893515

申请日：2022-08-23

Applicant: AMGEN INC.

Inventor： Christopher James SLOEY ,  Sekhar KANAPURAM ,  Huanchun CUI ,  Chio Mui CHAN ,  Elaheh BINABAJI

IPC: A61K39/395 ,  C07K1/36 ,  A61K9/00 ,  C07K1/16 ,  A61K47/18 ,  C07K16/40

CPC classification number: A61K39/3955 ,  A61K9/0019 ,  A61K39/39591 ,  A61K47/183 ,  C07K1/16 ,  C07K1/36 ,  C07K16/40 ,  C07K16/065

Abstract: Provided herein are formulations of PCSK9-binding polypeptides, such as those comprising evolocumab, that comprise N-acetyl arginine and have reduced viscosities when compared to formulations lacking N-acetyl arginine. Provided herein are also methods of formulating such compositions that are advantageous in that they conserve certain components. Such formulations comprising PCSK9-binding polypeptides can be administered to patients to treat and/or prevent PCSK9-related diseases, conditions, and disorders.